BEAM

Beam Therapeutics
$24.37
−$0.81 (−3.2%)Sep 10, 2026
2.7FairMoatMint rating

MoatMint rates Beam Therapeutics (BEAM) 2.7 out of 10, a research rating of the company's quality, value, growth, momentum and financial health. Its quality rating is 3.5 out of 10.

Key metrics

The numbers that frame BEAM today
Market cap
$2.52B
P/E (TTM)
-29.5
EV / FCF
-6.8
Gross margin
100%
EV / Sales
16.3
ROIC
-6.9%
Div yield
0%
Debt / equity
0.2
52wk Low
$19.57
52wk High
$38.26

BEAM stock rating

How BEAM scores on quality, value, growth, momentum and financial health
2.7out of 10
Fair overallNeutral business, expensive price
Quality3.5
Growth2.8
Momentum5.5
Value2.3
Financial Health3.8

Growth

Revenue and earnings trend for BEAM
RevenueNet income
See the full growth breakdown

Revenue and earnings trends, margins and the multi-year trajectory - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Cash flow & returns

Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture

Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Insider trading

Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade

See who is buying and selling, how much, and when - updated as new filings land.

Create a free account
Free foreverNo card required
Already a member? Log in

Frequently asked questions

Plain-English answers about BEAM
Is Beam Therapeutics a good buy?
Hold. Beam Therapeutics has weak quality and mixed momentum. The setup is mixed. Growth looks poor. That could put pressure on the long-term business case. We think Beam Therapeutics is selling at a very high price.
What is the market capitalization of BEAM?
Beam Therapeutics's market capitalization is $2.52B.
What is the P/E ratio for BEAM stock?
Beam Therapeutics's current P/E ratio is -29.5.
What is the 52-week high for BEAM stock?
The 52-week high for Beam Therapeutics is $38.26. The current close of $24.37 is 36.3% below that high.
What is the 52-week low for BEAM stock?
The 52-week low for Beam Therapeutics is $19.57. The current close of $24.37 is 24.5% above that low.
Does BEAM stock pay dividends?
Beam Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for BEAM?
Beam Therapeutics's Debt / Equity ratio is 0.23.